Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy.

Borthakur G, Dombret H, Schafhausen P, Brummendorf TH, Boissel N, Jabbour E, Mariani M, Capolongo L, Carpinelli P, Davite C, Kantarjian H, Cortes JE.

Haematologica. 2015 Jul;100(7):898-904. doi: 10.3324/haematol.2014.115279. Epub 2015 Apr 17.

2.

Pharmacological and toxicological aspects of 4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548): a novel antineoplastic agent.

Geroni C, Ripamonti M, Arrigoni C, Fiorentini F, Capolongo L, Moneta D, Marchini S, Della Torre P, Albanese C, Lamparelli MG, Ciomei M, Rossi R, Caruso M.

Cancer Res. 2001 Mar 1;61(5):1983-90.

3.

Phenyl sulfur mustard derivatives of distamycin A.

Cozzi P, Beria I, Caldarelli M, Capolongo L, Geroni C, Mazzini S, Ragg E.

Bioorg Med Chem Lett. 2000 Aug 7;10(15):1653-6.

PMID:
10937717
4.

Cytotoxic halogenoacrylic derivatives of distamycin A.

Cozzi P, Beria I, Caldarelli M, Capolongo L, Geroni C, Mongelli N.

Bioorg Med Chem Lett. 2000 Jun 5;10(11):1269-72.

PMID:
10866397
5.

The antitumor efficacy of cytotoxic drugs is potentiated by treatment with PNU 145156E, a growth-factor-complexing molecule.

Sola F, Capolongo L, Moneta D, Ubezio P, Grandi M.

Cancer Chemother Pharmacol. 1999;43(3):241-6.

PMID:
9923555
6.
7.

Sequence-specific DNA alkylation of novel tallimustine derivatives.

Marchini S, Cozzi P, Beria I, Geroni C, Capolongo L, D'Incalci M, Broggini M.

Anticancer Drug Des. 1998 Apr;13(3):193-205.

PMID:
9595033
8.

Estimation of the haematological toxicity of minor groove alkylators using tests on human cord blood cells.

Ghielmini M, Bosshard G, Capolongo L, Geroni MC, Pesenti E, Torri V, D'Incalci M, Cavalli F, Sessa C.

Br J Cancer. 1997;75(6):878-83.

9.

The alkylating antitumor drug tallimustine does not induce DNA repair.

Rossi R, Montecucco A, Capolongo L, Mezzina M, Chevallier-Lagente O, Sarasin A, Ciarrocchi G.

Anticancer Res. 1996 Nov-Dec;16(6B):3779-83.

PMID:
9042257
10.

Morpholinylanthracyclines: cytotoxicity and antitumor activity of differently modified derivatives.

Ripamonti M, Capolongo L, Melegaro G, Gornati C, Bargiotti A, Caruso M, Grandi M, Suarato A.

Invest New Drugs. 1996;14(2):139-46.

PMID:
8913834
11.

Decreased tyrosine phosphorylation in tumour cells resistant to FCE 24517 (tallimustine).

Ciomei M, Pastori W, Capolongo L, Geroni C, Melegaro G, Pennella G, Grandi M.

Br J Cancer. 1995 Dec;72(6):1504-8.

12.

Flow cytometric detection of glutathione S-transferase isoenzymes by quantitative immunofluorescence under nonsaturating conditions.

Pifferi A, Filippini C, Capolongo L, Codegoni A, Balconi G, Ubezio P, Tagliabue G.

Cytometry. 1995 Jun 1;20(2):134-45.

13.

Influence of structural modifications at the 3' and 4' positions of doxorubicin on the drug ability to trap topoisomerase II and to overcome multidrug resistance.

Capranico G, Supino R, Binaschi M, Capolongo L, Grandi M, Suarato A, Zunino F.

Mol Pharmacol. 1994 May;45(5):908-15.

PMID:
8190107
14.

Temperature influences both cytotoxicity and DNA nicking efficiency of the antitumor distamycin analogue FCE24517.

Montecucco A, Capolongo L, Melegaro G, Mondello C, Ciarrocchi G.

Anticancer Res. 1994 Jan-Feb;14(1A):189-92.

PMID:
8166448
15.

Reversal of multidrug resistance by new dihydropyridines with low calcium antagonist activity.

Capolongo L, Amboldi N, Ballinari D, Cozzi P, Melegaro G, Ripamonti M, Vaghi F, Grandi M.

Acta Oncol. 1994;33(7):787-91.

PMID:
7993647
16.

Growth-inhibitory properties of novel anthracyclines in human leukemic cell lines expressing either Pgp-MDR or at-MDR.

Mariani M, Capolongo L, Suarato A, Bargiotti A, Mongelli N, Grandi M, Beck WT.

Invest New Drugs. 1994;12(2):93-7.

PMID:
7860237
17.

Characterisation of a LoVo subline resistant to a benzoyl mustard derivative of distamycin A (FCE 24517).

Capolongo L, Melegaro G, Broggini M, Mongelli N, Grandi M.

Br J Cancer. 1993 Nov;68(5):916-9.

18.

Biological profile of FCE 24517, a novel benzoyl mustard analogue of distamycin A.

Pezzoni G, Grandi M, Biasoli G, Capolongo L, Ballinari D, Giuliani FC, Barbieri B, Pastori A, Pesenti E, Mongelli N, et al.

Br J Cancer. 1991 Dec;64(6):1047-50.

19.

Purine and 1-deazapurine ribonucleosides and deoxyribonucleosides: synthesis and biological activity.

Cristalli G, Vittori S, Eleuteri A, Grifantini M, Volpini R, Lupidi G, Capolongo L, Pesenti E.

J Med Chem. 1991 Jul;34(7):2226-30.

PMID:
2066996
20.

[New anthracyclines and multidrug resistance].

Grandi M, Ballinari D, Capolongo L, Pastori A, Ripamonti M, Suarato A, Spreafico F.

Haematologica. 1991 Jun;76 Suppl 3:181-3. Review. Italian. No abstract available.

PMID:
1752512
21.

Novel anthracycline analogs.

Grandi M, Pezzoni G, Ballinari D, Capolongo L, Suarato A, Bargiotti A, Faiardi D, Spreafico F.

Cancer Treat Rev. 1990 Sep;17(2-3):133-8. Review. No abstract available.

PMID:
2272029
22.

DNA damage and cytotoxicity of mitoxantrone and doxorubicin in doxorubicin-sensitive and -resistant human colon carcinoma cells.

Capolongo L, Belvedere G, D'Incalci M.

Cancer Chemother Pharmacol. 1990;25(6):430-4.

PMID:
2311171
23.

Antiproliferative properties of flavone acetic acid (NSC 347512) (LM 975), a new anticancer agent.

Capolongo LS, Balconi G, Ubezio P, Giavazzi R, Taraboletti G, Regonesi A, Yoder OC, D'Incalci M.

Eur J Cancer Clin Oncol. 1987 Oct;23(10):1529-35.

PMID:
3678316
24.

Representing cell cycle data.

Ubezio P, Capolongo L.

Cytometry. 1986 Nov;7(6):609-11.

Supplemental Content

Loading ...
Support Center